End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.324 SEK | +0.62% | +36.42% | +44.00% |
May. 14 | Cell Impact AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Cell Impact AB Signs Main Agreement with F.C.C | CI |
Sales 2022 | 91.53M 8.7M | Sales 2023 | 47.66M 4.53M | Capitalization | 133M 12.64M |
---|---|---|---|---|---|
Net income 2022 | -104M -9.88M | Net income 2023 | -121M -11.5M | EV / Sales 2022 | 7.76 x |
Net cash position 2022 | 120M 11.4M | Net cash position 2023 | 57.14M 5.43M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-7.96
x | P/E ratio 2023 |
-0.2
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.6% |
1 day | +0.62% | ||
1 week | +36.42% | ||
1 month | +110.39% | ||
3 months | +97.56% | ||
6 months | -21.74% | ||
Current year | +44.00% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vallin
CEO | Chief Executive Officer | 47 | 20-12-31 |
Human Resources Officer | 52 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 21-12-31 | |
Mats Franzén
CHM | Chairman | 55 | 22-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.324 | +0.62% | 12,722,900 |
24-05-30 | 0.322 | +9.71% | 27,844,200 |
24-05-29 | 0.2935 | -8.28% | 57,363,200 |
24-05-28 | 0.32 | +29.55% | 32,873,470 |
24-05-27 | 0.247 | +4.00% | 9,978,086 |
End-of-day quote Nasdaq Stockholm, May 30, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+44.00% | 18.19M | |
+65.45% | 4.02B | |
-0.16% | 2.03B | |
+1.30% | 2B | |
-3.63% | 1.82B | |
+4.42% | 1.52B | |
-8.35% | 1.51B | |
+10.63% | 1.29B | |
+46.09% | 1.25B | |
-33.97% | 1.21B |
- Stock Market
- Equities
- CI Stock